Stock EBAC EURO BIOT
Add to a list
To use this feature you must be a member
Log inSign up

EURO BIOT Stock

Equities

EBAC

KYG3167F1028

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-22 pm EDT 		5-day change 1st Jan Change
11.95 USD +1.44% Intraday chart for EURO BIOT -0.67% +6.79%
2023 European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index CI
2023 Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger. CI

Financials (USD)

Sales 2021 - Sales 2022 - Capitalization 166M
Net income 2021 1M Net income 2022 - EV / Sales 2021 -
Net cash position 2021 868K Net cash position 2022 308K EV / Sales 2022 -
P/E ratio 2021
112 x
P/E ratio 2022
590 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data

Chart EURO BIOT

Dynamic Chart

Latest news about EURO BIOT

European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index CI
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger. CI
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
European Biotech Acquisition, Oculis Strike Merger Agreement MT
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million. CI
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
Certain Class B Ordinary Shares of European Biotech Acquisition Corp. are subject to a Lock-Up Agreement Ending on 15-SEP-2021. CI
European Biotech Acquisition Corp.(NasdaqCM:EBAC) added to NASDAQ Composite Index CI
European Biotech Acquisition Corp. announced that it has received $4.55096 million in funding from Lsp Sponsor Ebac B.V. CI
European Biotech Acquisition Corp. Appoints Mohammad Sohail Fazeli to the Board CI
European Biotech Acquisition Corp. has completed an IPO in the amount of $120 million. CI
More news

Press releases EURO BIOT

EUROPEAN BIOTECH ACQUISITION CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K) AQ
EUROPEAN BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) AQ
EUROPEAN BIOTECH ACQUISITION CORP. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K) AQ
EUROPEAN BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) AQ
EUROPEAN BIOTECH ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
More press releases

Quotes and Performance

1 day+1.44%
Current month+6.79%
Current year+6.79%
More quotes

Highs and lows

3 years
0.00
Extreme 0
14.10
5 years
0.00
Extreme 0
14.10
10 years
0.00
Extreme 0
14.10
More quotes

Quotes

Date Price Change Volume
24-04-22 11.95 +1.70% 188,480
24-04-19 11.75 -0.25% 68,539
24-04-18 11.78 -1.01% 57,467
24-04-17 11.9 -0.83% 32,580
24-04-16 12 -0.25% 9,686

Delayed Quote Nasdaq, April 22, 2024 at 04:30 pm EDT

More quotes

Company Profile

European Biotech Acquisition Corp is a blanc check company based in the Netherlands. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to primarily seek to identify a company within the European life sciences industry. The aim of the Company is investments in therapeutic drug candidates in clinical development across a range of therapeutic areas, including oncology, diabetes, cardiology, central nervous system (CNS) and orphan diseases.
Sector
-
More about the company

Income Statement Evolution

More financial data
  1. Stock Market
  2. Equities
  3. EBAC Stock